anti-anxiety

Xaliproden is a compound that mimics the effects of nerve growth factor and is also a serotonin 5-HT1A receptor agonist.

Thioridazine hydrochloride (Mellaril) , an antipsychotic drug, is used in the therapy of psychosis and schizophrenia and shows serotonin antagonism or D4 selectivity.

Melitracen hydrochloride (Thymeol hydrochloride) , an antidepressant, is used as potential dopamine D1/2 receptor antagonist to treat depression.

Flibanserin (Girosa) is a serotonergic antidepressant used to treat hypoactive sexual desire disorder. Flibanserin has been associated with a low rate of minor serum aminotransferase elevations during treatment but has not been linked to instances of clinically apparent acute liver injury.

Emapunil (XBD-173) is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor, also known as the mitochondrial 18 kDa translocator protein or TSPO.

Vilazodone (SB659746A) is a selective serotonin (5-HT) reuptake inhibitor (SSRI) and a 5-HT-1A receptor partial agonist, with antidepressant and anti-anxiety activities. Vilazodone inhibits the reuptake of serotonin from the synaptic cleft while stimulating the release of 5-HT into the synaptic cleft. This increases the concentration of 5-HT in the synaptic cleft and potentiates serotonergic neurotransmission in the central nervous system.

2-(1-Piperazinyl)pyrimidine is used as an anti-anxiety drug.

(R)-5-Oxopyrrolidine-2-carboxylic acid (D-Pyroglutamic acid) is a cyclic derivative of glutamic acid, physiologically present in mammalian tissues. It releases GABA from the cerebral cortex and exhibits anti-anxiety effects in a simple approach-avoidance conflict situation in rats. In clinical pharmacology experiments, it significantly shortens the plasma half-life of ethanol during acute intoxication.

Arecoline is a natural alkaloid derived from areca nut in the palm family and is a potent nicotine and partial agonist of muscarinic acetylcholine receptors. Arecoline has anti-anxiety and anti-parasitic activity, can induce oxidative stress and can be used to study Alzheimer's disease and Alzheimer's disease.

1. 2,5-Dihydroxyacetophenone (Quinacetophenone) possess anti-anxiety, and neuroprotective qualities. 2. 2,5-Dihydroxyacetophenone (Quinacetophenone) reatment can induce a sustained activation of JNK, ERK1/2, and p38 MAPKs, it also can potentiate the pro-apoptotic and anti-proliferative effects of bortezomib in U266 cells. 3. 2,5-Dihydroxyacetophenone (Quinacetophenone) has anti-inflammatory activity in activated macrophages, raising the possibility that this compound has a therapeutic potential for inflammatory conditions. 4. 2,5-Dihydroxyacetophenone (Quinacetophenone) is an uncompetitive inhibitor of murine tyrosinase (K(I) 0.28mm), it strongly inhibits both melanogenesis and cellular tyrosinase activity in vitro in 3-isobutyl-1-methylxanthin-stimulated B16 mouse melanoma cells or in vivo in zebrafish and mouse models.

(±)-Myrtenol is the specific enantiomeric form of the bicyclic monoterpene alcohol known as Myrtenol. (-)-Myrtenol has been demonstrated to possess significant anti-anxiety effects in preclinical behavioral models; additionally, (-)-Myrtenol exhibits characteristics of gastric cell protection, suggesting potential therapeutic applications for gastrointestinal conditions.

Tebideutorexant is a selective antagonist of the orexin-1 receptor and has demonstrated anti-panic effects in both rodent and human models of panic-anxiety. Tebideutorexant provides valuable insights into orexin signaling pathways in stress response and has potential utility as a tool compound for psychiatric and neurobehavioral disorder research.

Lu AA33810 is a selective neuropeptide Y5 (NPY5) receptor antagonist with an oral activity and blood-brain barrier permeability advantage, exhibiting anti-anxiety and antidepressant-like effects at a Ki = 1.5 nM for rat receptors.

CP-409092 hydrochloride, a partial agonist of the GABAA receptor, exhibits anti-anxiety activity.

CP-409092 is a partial GABAA receptor agonist. It has anti-anxiety activity.

Oxyfenamate has anti-anxiety actions. It is also used in anxiety neuroses.

Fletazepam, a benzodiazepine derivative, exhibits sedative, anti-anxiety, and muscle-relaxant properties. It is utilized in neurological research.

Tuclazepam (KC 1956) is a derivative of the benzodiazepine class of drugs, exhibiting anti-anxiety and sedative properties.

Compound 6.4, also known as 5-HT7R antagonist 3, is a selective antagonist of the 5-HT7R with a Ki of 8 nM. It exhibits significantly less affinity towards D2R, 5-HT1AR, and 5-HT2AR with Ki values of 511 nM, 8930 nM, and 5786 nM, respectively. In mice, 5-HT7R antagonist 3 demonstrates anti-depressant and anti-anxiety activities.

Suproclone, a member of the cyclopyrrolone compound class, functions as a sedative and anxiolytic. Its mechanism of action involves the modulation of GABAA receptors to achieve its calming and anti-anxiety effects.

Delta8-THC acetate (Delta8-tetrahydrocannabinol) is a psychoactive cannabinoid that binds to the cannabinoid receptor 1 (CB1 receptor) and exhibits anti-nausea, appetite-stimulating, and anti-inflammatory effects. It may also offer neuroprotective benefits and has potential applications in research on anxiety and depression.

CD-10 is an orally active inhibitor of the Keap1-Nrf2 protein-protein interaction (PPI) that can penetrate the blood-brain barrier. It binds to Keap1 with a KD value of 193 nM. CD-10 exerts significant antioxidant and anti-inflammatory effects by activating the Keap1-Nrf2 pathway, demonstrated by reduced levels of MDA, IL-4, and IL-10, and increased expression of HO-1 protein. In a chronic unpredictable mild stress (CUMS) mouse model, CD-10 effectively alleviates anxiety and depressive behaviors and restores serum neurotransmitter levels by promoting Nrf2 nuclear translocation. CD-10 is applicable for research in depression.

G721-0282 is an orally active inhibitor of CHI3L1 that reduces the expression of inflammatory proteins and cytokines. It suppresses the activation of the NF-κB signaling pathway, inhibits neuroinflammation, and decreases anxiety-related behaviors. Additionally, G721-0282 significantly curtails the proliferation of osteosarcoma (OS) cells by inhibiting the STAT3 signaling pathway and induces apoptosis in OS cells by upregulating pro-apoptotic protein levels while downregulating anti-apoptotic protein levels. This compound is useful in the study of neuroinflammatory diseases and cancer.

BChE-IN-46 is a selective BChE inhibitor with the ability to penetrate the blood-brain barrier [eqBChE IC50 = 7.44 × 10^-5 μM, SI > 270,000, hBChE IC50 = 1.48 × 10^-3 μM]. It also exhibits COX-2 inhibitory activity (IC50 = 0.11 μM). BChE-IN-46 may offer neuroprotective effects, enhance acetylcholine levels, and improve cognitive dysfunction, anxiety, as well as learning and memory deficits. It is a potential candidate for the development of anti-Alzheimer's disease drugs.